Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Response to the Comments on Rimassa et al.: "Systemic Treatment Options in Hepatocellular Carcinoma".

Literature DB >> 32399436

Response to the Comments on Rimassa et al.: "Systemic Treatment Options in Hepatocellular Carcinoma".

Lorenza Rimassa¹, Tiziana Pressiani¹, Philippe Merle².

Abstract

Entities: Disease

Year: 2019 PMID： 32399436 PMCID： PMC7206598 DOI： 10.1159/000503302

Source DB: PubMed Journal: Liver Cancer ISSN： 1664-5553 Impact factor: 11.740

× No keyword cloud information.

6 in total

1. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Authors: Lorenza Rimassa; Eric Assenat; Markus Peck-Radosavljevic; Marc Pracht; Vittorina Zagonel; Philippe Mathurin; Elena Rota Caremoli; Camillo Porta; Bruno Daniele; Luigi Bolondi; Vincenzo Mazzaferro; William Harris; Nevena Damjanov; Davide Pastorelli; María Reig; Jennifer Knox; Francesca Negri; Jörg Trojan; Carlos López López; Nicola Personeni; Thomas Decaens; Marie Dupuy; Wolfgang Sieghart; Giovanni Abbadessa; Brian Schwartz; Maria Lamar; Terri Goldberg; Dale Shuster; Armando Santoro; Jordi Bruix
Journal: Lancet Oncol Date: 2018-04-03 Impact factor: 41.316

2. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.

Authors: Philippe Merle; Jean-Frederic Blanc; Jean-Marc Phelip; Gilles Pelletier; Jean-Pierre Bronowicki; Yann Touchefeu; Georges Pageaux; René Gerolami; François Habersetzer; Eric Nguyen-Khac; Andrea Casadei-Gardini; Ivan Borbath; Albert Tran; Henning Wege; Amr Shafik Saad; Massimo Colombo; Armand Abergel; Carine Richou; Imam Waked; Nelson S Yee; Audrey Molé; Pierre Attali; Julie Le Boulicaut; Bérangère Vasseur
Journal: Lancet Gastroenterol Hepatol Date: 2019-04-04

3. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.

Authors: Shukui Qin; Yuxian Bai; Ho Yeong Lim; Sumitra Thongprasert; Yee Chao; Jia Fan; Tsai-Shen Yang; Vajarabhongsa Bhudhisawasdi; Won Ki Kang; Yu Zhou; Jee Hyun Lee; Yan Sun
Journal: J Clin Oncol Date: 2013-08-26 Impact factor: 44.544

4. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors: Andrew X Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo
Journal: Lancet Oncol Date: 2019-01-18 Impact factor: 41.316

5. Sorafenib alone vs. sorafenib plus GEMOX as 1^st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.

Authors: Eric Assenat; Georges-Philippe Pageaux; Simon Thézenas; Jean-Marie Peron; Yves Bécouarn; Jean-François Seitz; Philippe Merle; Jean-Frédéric Blanc; Olivier Bouché; Mohamed Ramdani; Sylvain Poujol; Hélène de Forges; Marc Ychou; Valérie Boige
Journal: Br J Cancer Date: 2019-04-04 Impact factor: 7.640

Review 6. Systemic Treatment Options in Hepatocellular Carcinoma.

Authors: Lorenza Rimassa; Tiziana Pressiani; Philippe Merle
Journal: Liver Cancer Date: 2019-05-29 Impact factor: 11.740